Clinical Trials Browser

Phase 1/2 × INDUSTRY × lenvatinib × Clear all

NCT04300556 2026-06-04

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Phase 1/2 Recruiting

BreastGynecologicThoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04938817 2026-06-01

KEYNOTE-B98

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

NCT04305054 2026-05-28

KEYMAKER-U02

Phase 1/2 Completed

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05319730 2026-05-26

MK-3475-06B

Phase 1/2 Recruiting

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT04626479 2026-05-18

MK-3475-03A

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04977453 2026-05-15

Keynote B59

Phase 1/2 Recruiting

GenitourinaryGynecologic

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

NCT04626518 2026-05-06

KEYMAKER-U03

Phase 1/2 Active not recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT05024214 2026-03-25

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Phase 1/2 Active not recruiting

GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT02861573 2026-02-17

KEYNOTE-365

Phase 1/2 Recruiting

Metastatic Castration-Resistant Prostate Cancer

NCT05342636 2025-12-17

A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)

Phase 1/2 Completed

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT07282509 2025-12-15

Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer

Phase 1/2 Not yet recruiting

Gastrointestinal

Advanced Hepatocellular Carcinoma (HCC)

NCT04700072 2025-10-28

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05091346 2025-10-24

A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors

Phase 1/2 Completed

89 enrolled 24 charts

DermatologicGastrointestinal

Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT03781934 2025-07-01

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT04444167 2024-04-25

A Study of Anti-PD-1/CTLA-4 Bispecific AK104 Plus Lenvatinib in First-line Advanced Hepatocellular Carcinoma

Phase 1/2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03245151 2023-08-30

Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors

Phase 1/2 Completed

64 enrolled 29 charts

Glioma, Recurrence, Rhabdomyosarcoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Neoplasms

NCT02432274 2023-07-11

Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma

Phase 1/2 Completed

117 enrolled 32 charts

Neoplasms, Osteosarcoma

NCT01133756 2023-06-22

E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125

Phase 1/2 Terminated

7 enrolled 6 charts

Ovarian Neoplasms

NCT05740215 2023-02-22

Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors

Phase 1/2 Unknown

Other solid neoplasm

Solid Tumors

NCT01433991 2021-06-08

A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Phase 1/2 Terminated

30 enrolled 42 charts

Other solid neoplasm

Advanced Solid Tumors

NCT01136733 2019-02-27

A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment

Phase 1/2 Completed

173 enrolled 28 charts

Carcinoma, Renal Cell

NCT00946153 2019-02-01

Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Completed

66 enrolled 18 charts

Gastrointestinal

Carcinoma, Carcinoma, Hepatocellular

NCT01133977 2016-10-10

E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma

Phase 1/2 Completed

97 enrolled 8 charts

Melanoma